M&A Deal Summary |
|
|---|---|
| Date | 2021-06-02 |
| Target | Constellation Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | MorphoSys |
| Deal Type | Add-on Acquisition |
| Deal Value | 1.7B USD |
| Advisor(s) | Centerview Partners (Financial) Wachtell, Lipton, Rosen & Katz (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1992 |
| Sector | Life Science |
| Revenue | 278M EUR (2022) |
MorphoSys is a global biopharmaceutical company developing innovative medicines in oncology. MorphoSys was formed in 1992 and is based in Planegg, Germany.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2021 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-05-07 |
Lanthio Pharma BV
Groningen, Netherlands Lanthio Pharma BV is a biopharmaceutical company. |
Buy | - |